Triethylene glycol, an active component of Ashwagandha (Withania somnifera) leaves, is responsible for sleep induction by Kaushik Mahesh K. et al.
Triethylene glycol, an active component of
Ashwagandha (Withania somnifera) leaves, is
responsible for sleep induction
著者 Kaushik Mahesh K., Kaul Sunil C., Wadhwa Renu,
Yanagisawa Masashi, Urade Yoshihiro
journal or
publication title
PLOS ONE
volume 12
number 2
page range e0172508
year 2017-02
権利 (C) 2017 Kaushik et al. This is an open access
article distributed under the terms of the
Creative Commons Attribution License, which
permits unrestricted use, distribution, and
reproduction in any medium, provided the
original author and source are credited.
URL http://hdl.handle.net/2241/00145727
doi: 10.1371/journal.pone.0172508
Creative Commons : 表示
http://creativecommons.org/licenses/by/3.0/deed.ja
RESEARCH ARTICLE
Triethylene glycol, an active component of
Ashwagandha (Withania somnifera) leaves, is
responsible for sleep induction
Mahesh K. Kaushik1,2*, Sunil C. Kaul3, Renu Wadhwa3, Masashi Yanagisawa2,
Yoshihiro Urade1*
1 Department of Molecular Sleep, International Institute for Integrative Sleep Medicine (WPI-IIIS), University
of Tsukuba, 1-1-1 Tennodai, Tsukuba, Ibaraki, Japan, 2 Department of Molecular Genetics, International
Institute for Integrative Sleep Medicine (WPI-IIIS), University of Tsukuba, 1-1-1 Tennodai, Tsukuba, Ibaraki,
Japan, 3 Drug Discovery and Assets Innovation Lab, DBT-AIST International Laboratory for Advanced
Biomedicine (DAILAB), National Institute of Advanced Industrial Science and Technology, Higashi 1-1-1,
Tsukuba, Ibaraki, Japan
* kaushik.m.k.kb@u.tsukuba.ac.jp (MKK); urade.yoshihiro.ft@u.tsukuba.ac.jp (YU)
Abstract
Insomnia is the most common sleep complaint which occurs due to difficulty in falling asleep
or maintaining it. Most of currently available drugs for insomnia develop dependency and/or
adverse effects. Hence natural therapies could be an alternative choice of treatment for
insomnia. The root or whole plant extract of Ashwagandha (Withania somnifera) has been
used to induce sleep in Indian system of traditional home medicine, Ayurveda. However, its
active somnogenic components remain unidentified. We investigated the effect of various
components of Ashwagandha leaf on sleep regulation by oral administration in mice. We
found that the alcoholic extract that contained high amount of active withanolides was inef-
fective to induce sleep in mice. However, the water extract which contain triethylene glycol
as a major component induced significant amount of non-rapid eye movement sleep with
slight change in rapid eye movement sleep. Commercially available triethylene glycol also
increased non-rapid eye movement sleep in mice in a dose-dependent (10–30 mg/mouse)
manner. These results clearly demonstrated that triethylene glycol is an active sleep-
inducing component of Ashwagandha leaves and could potentially be useful for insomnia
therapy.
Introduction
Insomnia and other sleep disorder such as restless leg syndrome are common complaints
among the middle-aged population. Insomnia is one of the most common neuropsychiatric
disorders, with an estimated incident of 10–15% in general population and 30–60% in elderly
population [1]. It is closely linked with certain other diseases including obesity, cardiovascular
diseases, depression, anxiety, mania deficits etc., due to behavioral, hormonal and neurochem-
ical alternations [2, 3]. It also causes huge economic loss to the society by means of traffic acci-
dent, less productivity at work and clinical cost for the treatment. Most commercially available
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drugs that are used to treat insomnia are based on benzodiazepines, modulation of melatonin
or histamine based mechanism. These drugs are often associated with major or minor adverse
effects that includes dependency, withdrawal symptoms or other side effects [4–8]. Recently
approved orexin receptor-based insomnia therapy, suvorexant (Balsomra1), also showed side
effects [9]. Hence, natural compounds with sleep-inducing potential are an alternative to avoid
side effects and dependency of those synthetic drugs that are currently used to treat insomnia.
Ashwagandha (Withania somnifera) is a central herb in Ayurveda, the traditional medicine
system native to India. It has been used for thousands of years in Ayurvedic medicine and clas-
sified as a Rasayana (chemical) herb that promotes body- and brain-health by multiple ways
including, increasing the stress tolerance and strengthening the immune system [10]. As signi-
fied by its name “somnifera- meaning sleep-inducing”, it has been recommended for sound
sleep through centuries. It is believed that Ashwagandha is an adaptogen (natural compound
that help the body adapt to stress) that corrects the imbalance between immune and neuroen-
docrine system to normalize the bodily functions under stressed conditions by targeting hypo-
thalamic-pituitary-adrenal gland axis [11]. Pre-treatment with Ashwagandha extract has
protective effects against stress, cancer and age-associated neurodegenerative conditions [12–
15]. The root extract administration induced sleep in rats after oral administration [16, 17].
However, those previous studies used root extracts that can have slightly overlapping but dif-
ferent composition with that of our study. Moreover, the active component of Ashwagandha,
which is responsible for sleep induction was still remain unidentified. Based on current avail-
able studies, we analyzed the effect of alcoholic and water extracts of Ashwagandha leaves on
sleep quality and quantity by recording electroencephalogram (EEG) and electromyogram
(EMG) in mice. We found that the triethylene glycol (TEG) in the water extract induced sleep
in mice in a dose-dependent manner and is a natural sleep-inducing molecule.
Materials and methods
Animals
We used male C57BL/6 mice weighing 24–30 g (11–13 weeks) for experiments. C57BL/6 mice
were obtained from Japan SLC (Shizuoka, Japan), and housed in an insulated sound-proof
recording room maintained at an ambient temperature of 23 ± 0.5˚C with a relative humidity
of 50 ± 5% on an automatically controlled 12 h light/dark cycle (light on at 0500; illumination
intensity above 100 lux). Mice were fed ad libitum and given sufficient water. The experimental
protocols were approved by the University of Tsukuba Animal Ethics Committee, and every
effort was made to minimize the number of animals used as well as any pain and discomfort
(Animal ethical approval number; 16086).
Surgery
Under anesthesia using pentobarbital (50 mg/kg, intraperitoneally) mice were chronically
implanted with EEG and EMG electrodes for polysomnography, as previously described [18].
Briefly, the implant consisted of 2 stainless steel screws (1 mm diameter) serving as EEG elec-
trodes, one of which was placed epidurally over the right frontal cortex (1.0 mm anterior and
1.5 mm lateral to bregma) and the other over the right parietal cortex (1.0 mm anterior and 1.5
mm lateral to lambda). Two Teflon coated stainless steel wires (0.2 mm in diameter), which
were placed bilaterally into the trapezius muscles, served as EMG electrodes. Both EEG and
EMG electrodes were connected to a micro connector. The whole assembly was then fixed to
the skull with self-curing dental acrylic resin. Antibiotic and analgesic drugs were administered
up to 5 days post-operatively.
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EEG/EMG recording and analysis
After 8–10 days of post-operative recovery, the mice were placed in experimental cages for a
4-day habituation/acclimatization period and connected with counterbalanced recording
leads. Baseline EEG/EMG was recorded for 24 h starting onset of dark phase. All mice that
were subjected to EEG/EMG recordings received vehicle and multiple doses of Ashwagandha
leaf extracts or pure TEG (10 mg, 20 mg, and 30 mg/mouse) on different days and any two
administrations were separated by, at least, 2 days. Each EEG/EMG recording and drug
administration was performed per os (p.o.), at the onset of dark phase (17:00 h). Cortical EEG
and EMG signals were amplified and filtered (EEG, 0.5–30 Hz; EMG, 20–200 Hz), then digi-
tized at a sampling rate of 128 Hz, and recorded by using SleepSign software (Kissei Comtec,
Nagano, Japan) as previously described [19]. Polysomnographic recordings were scored with
automated analysis, off-line, in 10-s epochs as wakefulness, rapid eye movement (REM) and
non-REM (NREM) sleep by SleepSign software, using standard criteria [19, 20]. The defined
sleep–wake stages were visually examined and corrected, wherever necessary. Spectral analysis
of EEG by fast Fourier transformation (FFT) was performed, and the EEG power densities of
each 0.5- Hz bin were averaged by calculating the percentage of each bin with respect to the
total power in the range of 0.5–35 Hz.
Preparation of leaf extract of Ashwagandha
Ashwagandha plants were raised in Nihari-mura, Ibaraki, Japan and kindly provided for
experimental use. Alcoholic extract of Ashwagandha leaves were prepared as described previ-
ously [21, 22]. Briefly, the leaves of Ashwagandha were washed, air-dried and ground to a fine
powder. The fine leaf powder was extracted by Soxhlet method. The leaf powder (40 g) was
exhaustively extracted with methanol (60˚C) in Soxhlet apparatus for 100–110h. Methanol was
distilled-off to concentrate the extract. It was made aqueous by adding double-distilled water
and was then extracted with hexane to remove chlorophyll and other pigments. Residual aque-
ous methanolic solution was re-extracted with diethyl ether using separating funnel. Diethyl
ether was evaporated and the extract was solubilized in sterile DMSO for use. Water extract
was prepared as described previously [15]. For cyclodextrin-assisted aqueous extraction of
Ashwagandha leaves, the dried leaf powder (10% w/v) was mixed with aqueous solution of
7.5% gamma-cyclodextrin. The mixture was stirred for 24 h at 37˚C with slow shaking (90
rpm) in TAITEC Bio-Shaker BR-43FL. The slurry was centrifuged at 3500 rpm for 10 min and
the supernatant was filtered through 0.45-micron filter.
Statistical analysis
All data were expressed as mean ± SEM. The statistical significance of time-course changes for
sleep-wake profiles and power density were analyzed by paired t-test. Dose dependency data of
wake, REM and NREM sleep, number of sleep-wake bouts, episode duration and stage transi-
tion were analyzed using one-way ANOVA followed by Least Square Difference (LSD) post-
hoc test. In all of the cases, p<0.05 was considered as significant.
Results
TEG, but not withanone or withaferin A, caused induction of sleep in
mice
Ashwagandha leaf extracts were prepared via two methods viz alcohol-based (Ethanol) extrac-
tion and water based-extraction (named; water & cyclodextrin extracts). These extracts were
tested for their sleep-inducing properties in mice after p.o. administration followed by EEG/
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EMG recordings. Oral administration of the ethanol extract failed to change either NREM or
REM sleep in mice (Fig 1A). Total amount of REM and NREM sleep remain indistinguishable
between vehicle (5% DMSO) and ethanol extract (200 mg/kg) administration (Fig 1C), suggest-
ing that withanolides (withaferin A and withanone), major components of the leaf extract, can
be ruled out for the sleep-inducing property of Ashwagandha. On the other hand, both water
and cyclodextrin extracts, increased NREM sleep significantly as compared to vehicle adminis-
tration (Fig 1B). Total amount of NREM sleep over 12 h was also significantly increased after
administration of those extracts (Fig 1C).
TEG-induced NREM, but not REM, sleep in wild-type mice
Previously, TEG has been identified as an active component present in water extracts of Ash-
wagandha leaves (10). Similarly, cyclodextrin extract also had high percentage of TEG. We
then investigated the sleep-inducing potential of TEG by p.o. administration in mice. Typical
EEG delta power traces, EMG integral and hypnograms of a mouse after p.o. administration of
vehicle (Fig 2A) or TEG (Fig 2B). Whereas the animal remained mainly awake after vehicle
administration, TEG-treated animals fell asleep within few minutes after the administration.
EEG traces during both vehicle and TEG treatment showed clear increase in delta power, char-
acteristic to NREM sleep. TEG treated animal showed increased amount of delta power bouts
compared to vehicle. EMG integral decreased in power corresponding to the increase in EEG
delta power (Fig 2A and 2B). Time course analysis of hourly amounts of NREM, REM sleep
and wake revealed that p.o. administration of TEG induced NREM sleep (Fig 2C) as compared
to vehicle administration without change in REM sleep (Fig 2D), and with a concomitant
decrease in wake (Fig 2E). This increase in NREM was statistically significant up to 4 h after
administration. When we tested dose dependency, TEG-dependent NREM sleep was increased
from 204.6±5.1 min/12 h after vehicle to 251.1±8.8, 281.1±6.9 and 287.9±5.4 min/12 h after
administration of TEG at doses of 10, 20 and 30 mg/mouse, respectively, during dark phase
(Fig 2F). Total amount of sleep, that was calculated by adding REM and NREM sleep (Fig 1G),
and total percentage of sleep amount (S1 Fig) during dark phase, also showed dose-dependent
increase. Total amount of wake was concomitantly decreased with increasing TEG dose (from
498.5±4.3 min/12 h to 413.6±7.1 min/12 h; Fig 2F). Similarly, dose-dependent decrease in total
wake percentage was apparent after administration of increasing doses of TEG (S1 Fig). The
amounts of REM and NREM sleep induced by TEG administration were comparable to that of
positive control (doxepin; 4.5 μg/mouse; S2 Fig). Next, we adopted cage change strategy,
whereby, mice were transferred to clean cages, to induce sleep deprivation for 1–2 h. We
observed that TEG failed to induce changes in wake, REM, or NREM sleep under the condi-
tion of brief sleep deprivation (S3 Fig).
TEG decreased NREM sleep onset latency and induces physiological
sleep
NREM sleep onset latency was calculated by observing appearance of at least two consecutive
NREM epochs following vehicle or TEG administration. We observed significant decrease in
NREM onset latency with increasing doses of TEG (Fig 3A). EEG power density of REM (S4
Fig) and NREM (Fig 3B) during 12 h dark phase was indistinguishable between vehicle and
TEG treatment, indicating that TEG administration induced physiologically similar sleep
(which can be defined as naturally occurring sleep in healthy individuals, and can be assessed
by means of power density as a marker for the deepness of sleep) without affecting EEG power
density. No abnormalities in EEG pattern or sleep architecture, such as sleep rebound or sleep
loss, was observed during 24 h period following initial effect of TEG on NREM sleep.
Triethylene glycol in Ashwagandha induces sleep
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Fig 1. Oral administration of various extracts from Ashwagandha leaves in mice and their effect on sleep-wakefulness. (A) Hourly plots of NREM
and REM sleep after p.o. administration of vehicle (black circles) or alcoholic extract of Ashwagandha leaves (orange circles; n = 5). (B) Hourly plots of NREM
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TEG induces sleep by increasing number of NREM episodes and by
decreasing wake episode duration
The sleep-wake architecture and quality was evaluated by calculating episode numbers, epi-
sode duration, stage transitions and NREM sleep stage distribution during dark phase. The
episode number of NREM sleep (92.5±6.60) and wake (90.3±7.16) were significantly increased
after treatment of TEG (30 mg/mouse) compared to vehicle (74.8±5.68 & 74.7±5.81, respec-
tively; Fig 4A). TEG treatment also decreased the mean duration of wake episodes (284.7
±24.67 sec/episode) compared to vehicle treatment (401.0±29.55 sec/episode; Fig 4B). Further,
there was significant increase in number of transitions from wake to NREM (89.3±7.16/12 h)
and from NREM to wake (70.5±7.20/12 h) after TEG treatment compared to vehicle (73.7
±5.81 & 56.7±5.19/12 h, respectively; Fig 4C). TEG treatment increased the number of short
NREM sleep episodes (<240 sec) leaving long episodes (>240 sec) unaffected (Fig 4D).
Discussion
The increase in sleep following administration of Ashwagandha leaf extract was also supported
by Ayurveda (Traditional medicine system of India). Whereby, ashwagandha powder (root,
leaves or whole plant), induces sleep in humans on oral consumption. Further, oral administra-
tion of Ashwagandha root extract induced sleep in rats [16, 17]. Hence, we dissected out the
role of various know components of Ashwagandha in sleep regulation. Withaferin-A and witha-
none (withanolides), are the major biologically active constituents of Ashwagandha leaves [22,
23] and believed to be involved in majority of biological functions of Ashwagandha. Withano-
lides are involved in various bodily functions such as anti-cancer activity [22], neuroprotection
and anti-stress activity [24], recovery from amnesia [14], anti-mutagenic [25]. However, in our
study, ethanol extract that contain high ratio of withaferin A and withanone, failed to induce
sleep in mice, indicating that withanolides might not be involved in sleep promotion (Fig 1A).
However, specified withanolides need to be tested directly, before completely ruling out witha-
nolides and their derivatives for their sleep-inducing property. Sleep promotion was observed
by water extracts that contained TEG and only a low level of withanolide (Fig 1B) and TEG itself
(Fig 2). TEG administration increased sleep in a dose-dependent manner (Fig 2). Recently, anti-
cancer activity of TEG and its involvement in neuroprotection has been reported [15, 26]. As
shown in Fig 2G, TEG administration did not alter the NREM EEG power density, implying
that quality of sleep was not affected by TEG administration and that TEG-induced sleep was
physiological. In contrast, benzodiazepines affects the quality of sleep and reduced EEG power
[27]. Hence, TEG can be a better alternative to currently available drugs, because it promotes
physiological sleep (naturally occurring sleep in healthy individuals).
Sleep regulation has two components viz sleep generation, which is signified by number or
frequency of NREM episodes, and sleep maintenance reflected in terms of NREM episode
duration. TEG increased frequency of NREM sleep episodes suggesting that TEG has potential
to generate sleep and that TEG increases NREM sleep by frequently entering into sleep via tar-
geting sleep generation mechanism. Moreover, TEG promoted sleep by increasing the number
of shorter episodes of NREM sleep (Fig 3D), suggesting that TEG is able to generate sleep
more frequently, thus increasing total amount of NREM sleep.
and REM sleep after p.o. administration of vehicle (black circles) or water extracts of Ashwagandha leaves; cyclodextrin extract (blue circle) and water extract
(magenta circles; n = 6). Arrows indicate time of p.o. administration. Black and white horizontal bars indicate 12 h dark and 12 h light period. (C) Changes in
total amount of NREM (left graph) and REM sleep (right graph) during dark phase after p.o. administration of vehicle (black bars) and various Ashwagandha
leaf extracts (colored bars). All administrations were done at the onset of dark period (17:00 h). Data presented as mean ± SEM; *p0.05, **p0.01 vs
vehicle by using paired t-test.
doi:10.1371/journal.pone.0172508.g001
Triethylene glycol in Ashwagandha induces sleep
PLOS ONE | DOI:10.1371/journal.pone.0172508 February 16, 2017 6 / 12
Triethylene glycol in Ashwagandha induces sleep
PLOS ONE | DOI:10.1371/journal.pone.0172508 February 16, 2017 7 / 12
TEG is primarily used for industrial purpose and very little is known about its usefulness to
the biological systems. Available information is limited to animal studies, except few case
reports of accidental consumption of TEG. Various animal studies showed little or no TEG
toxicity, suggesting that its lower volumes are safe in biological system, but higher volumes
could be dangerous [28]. A reported case of accidental TEG consumption resulted in coma
and metabolic acidosis, however, treated via ethanol infusion [29]. Another case of TEG poi-
soning was treated by using 4-methylpyrazole [30]. These incidences, however, clearly suggests
that toxicological properties of TEG need to be studied in detail before its use is advised in
humans. Study on TEG metabolism suggests that maximum portion of TEG (91–98%) follow-
ing administration in rats and rabbits, eliminated in urine (84–94%), and minor portion via
feces and expiration. On metabolic oxidation it produces amonocarboxylic acid, ethylenediox-
ydiacetic acid and oxalic acid [31]. Almost nothing is known about TEG’s absorption or blood
levels, whether or not it crosses blood brain barrier and its target organ.
Fig 2. Dose-dependent increase in NREM sleep and decrease in wakefulness by p.o. administration of TEG
in mice. (A, B) Typical examples of EEG delta power (0.5–4 Hz), EMG integral, and hypnograms of a mouse after p.
o. administration of vehicle (A) or TEG (B). Hypnograms represent concatenated 10-sec epochs of EEG/EMG
activity, scored as wake, REM, and NREM sleep. Three hours after p.o. administration are shown. Wake, REM are
shown in gray while NREM sleep shown in black. (C, D and E) Hourly plots of NREM, (C), REM sleep (D) and wake
(E) in mice after p.o. administration of vehicle (black circles) and TEG (30 mg/mouse; magenta circles). Significant
increase in NREM sleep and decrease in wake are apparent in the graphs at least up to 4 h after TEG administration.
Black and white horizontal bars indicate 12 h dark and 12 h light period. (F) Total amount of wake, REM, and NREM
sleep over 12 h dark period after vehicle (black bars) and various doses of TEG (colored bars) administration. There
was a dose-dependent increase in NREM sleep with concomitant decrease in wake. (G) Graph shows total amount
of sleep during dark phase (12 h) following vehicle (black bar) and various doses of TEG (color bars) administration.
All administrations were done at the onset of dark period (17:00 h). Data presented as mean ± SEM; n = 6; *p0.05,
**p0.01 vs vehicle by using paired t-test for time course data (C, D and E), and one-way ANOVA followed by least
square difference (LSD) post-hoc test for dose-response data (F and G). # #p0.01 vs TEG (10 mg/head).
doi:10.1371/journal.pone.0172508.g002
Fig 3. TEG decreased NREM sleep onset latency and induces physiological sleep. (A), Graph shows
changes in NREM sleep onset latency after vehicle (black bar) and various doses of TEG (color bars) admini-
stration. (B), Graph shows NREM EEG power density over 12 h dark phase following vehicle (black line) and
TEG (magenta line) administration in mice. Data presented as mean ±SEM; n = 6; *p0.05, **p0.01 vs
vehicle by one-way ANOVA followed by least square difference (LSD) post-hoc test.
doi:10.1371/journal.pone.0172508.g003
Triethylene glycol in Ashwagandha induces sleep
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Conclusion
Insomnia and poor quality of sleep results in chronic sleep loss that is associated with various
other sleep and metabolic disorders. Unlike conventional therapy available to treat insomnia,
those develop dependency and side effects, we were interested to identify a natural compound
with sleep-inducing potential. In this study, we demonstrated that TEG, which is also an active
component of Ashwagandha leaves, is a potent sleep-inducing small molecule. Ashwagandha
leaf or root crude powder itself is able to enhance the quality of sleep. Here we showed that a
sleep-promoting active component present in Ashwagandha leaves is TEG and validated the
sleep inducing potential of TEG by animal experiments. Further studies are needed to delin-
eate its molecular targets and sleep-promoting pathways.
Supporting information
S1 Fig. TEG decreased total wake percentage and increased total sleep percentage. Graph
shows changes total wake (A) and total sleep (B) percentage during 12 h dark phase after vehi-
cle (black bar) and various doses of TEG (color bars) administration in mice. Data presented
as mean ± SEM; n = 6; p0.05, p0.01 vs vehicle, and # #p0.01 vs TEG (10 mg/head), by
one-way ANOVA followed by least square difference (LSD) post-hoc test.
(PDF)
Fig 4. TEG induces sleep by targeting sleep generation mechanism. Graphs represent changes in number of episodes (A),
stage duration (B) of wake, REM and NREM sleep during 12 h dark phase after p.o. administration of vehicle (black bars) and
various doses of TEG (colored bars). (C) Stage transition between wake, REM, and NREM sleep in mice after vehicle or TEG
treatment. (D) NREM sleep stage distribution was calculated by averaging various NREM episodes within specific time durations,
in mice after vehicle and TEG administration. Data presented as mean ± SEM; n = 6; *p0.05, **p0.01 vs vehicle; +p0.05, +
+p0.01 vs 10 mg/mouse TEG, by using one-way ANOVA followed by least square difference (LSD) post-hoc test. NR: NREM
sleep; W: Wake; R: REM sleep.
doi:10.1371/journal.pone.0172508.g004
Triethylene glycol in Ashwagandha induces sleep
PLOS ONE | DOI:10.1371/journal.pone.0172508 February 16, 2017 9 / 12
S2 Fig. TEG induced NREM sleep was comparable to positive control (doxepin). Graph
shows time course changes in NREM sleep after TEG (magenta line) and doxepin (green line)
administration in mice. Data presented as mean ± SEM; n = 6; p0.05, p0.01 vs vehicle
by one-way ANOVA followed by least square difference (LSD) post-hoc test.
(PDF)
S3 Fig. TEG failed to induce changes in NREM sleep in sleep deprived mice. Vehicle or
TEG administration was immediately followed by change of mice cage, to induce wakefulness.
Graph shows time course changes in REM (upper graph) and NREM (lower graph) sleep after
vehicle (gray line) and TEG (blue line) administration in mice. Data presented as mean ± SEM;
n = 6; statistical test applied was paired t-test.
(PDF)
S4 Fig. TEG induced changes in REM sleep power density. Graph shows changes in REM
sleep power density after vehicle (black line) and TEG (magenta line) administration in mice.
(PDF)
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